



Mains Practice Question

Case Study

Dr. Sharma, a senior scientist at a renowned biotechnology company, leads a research team developing a drug to treat a rapidly spreading variant of a new viral infectious disease. With cases increasing worldwide and in India, there's immense pressure on Dr. Sharma's team to expedite the drug trials. The company seeks to capitalize on the significant market potential and gain a first-mover advantage.

During a team meeting, senior members propose shortcuts to accelerate the clinical trials and secure quick approvals. These include manipulating data to exclude negative outcomes and selectively report positive results, bypassing informed consent procedures, and using patented compounds from a rival company instead of developing their own. Dr. Sharma feels uncomfortable with these shortcuts but realizes that meeting the targets is impossible without employing such means. She now faces a difficult decision that pits scientific integrity and patient safety against market pressures and the urgent need for a treatment.

1. Who are the stakeholders involved in this situation?
2. What are the ethical dilemmas faced by Dr. Sharma?
3. What course of action should Dr. Sharma take in this scenario?

11 Oct, 2024 GS Paper 4 Case Studies

Introduction:

Dr. Sharma, a senior scientist, is leading a team developing a drug for a rapidly spreading viral disease. Facing immense pressure to **expedite trials and secure approvals**, her colleagues propose unethical shortcuts, including data manipulation and bypassing informed consent.

- Dr. Sharma is conflicted **between maintaining scientific integrity and meeting urgent market demands for the treatment**. She must decide whether to prioritize ethics or give in to business pressures.

Body:

1. Who are the stakeholders involved in this situation?

Stakeholders	Role/Interest in the Situation
Dr. Sharma (Senior Scientist)	Faces an ethical dilemma between maintaining scientific integrity and succumbing to pressure to expedite drug development.
Research Team	Pressuring Dr. Sharma to take unethical shortcuts to meet deadlines, driven by both professional achievement and market advantage.
Biotechnology Company	Aims to capitalize on the drug's potential, seeking quick market approval and first-mover advantage to boost profits.
Patients	Rely on the development of a safe and effective drug, vulnerable

(Worldwide and in India)	to risks if trials are manipulated or data misrepresented.
Regulatory Bodies	Tasked with ensuring the safety, efficacy, and ethical standards of drug trials, responsible for protecting public health.
Rival Biotechnology Company	Holds patents on compounds proposed for unauthorized use, has intellectual property rights at stake.
Scientific Community	Relies on the integrity of research and data, as any manipulation undermines public trust in scientific advancements.
Healthcare Providers	Responsible for administering treatments, potentially put in a compromising position if drug safety is compromised.
Investors/Shareholders	Interested in the company's financial success, potentially encouraging shortcuts to expedite the drug's release.
Global Public Health Authorities	Focused on addressing the pandemic with safe and effective treatments, relying on truthful reporting from biotech companies.

2. What are the ethical dilemmas faced by Dr. Sharma?

- **Scientific integrity vs. Expedited Results:** Dr. Sharma must choose between maintaining scientific rigor and integrity or taking shortcuts to accelerate the drug development process.
 - **Manipulating data and selectively reporting** results violates fundamental principles of scientific research and could lead to unreliable or even dangerous outcomes.
- **Patient Safety vs. Rapid Drug Deployment:** There's a tension between ensuring thorough safety testing and getting a potentially life-saving drug to market quickly.
 - Bypassing informed consent procedures denies patients their **right to make informed decisions** about their treatment and participation in trials.
- **Professional Ethics vs. Organizational Pressure:** As a scientist, Dr. Sharma has a **responsibility to uphold ethical standards in research**. However, she's under pressure from her organization to meet targets and deadlines.
 - This creates a conflict between her professional integrity and her role as an employee and team leader.
- **Intellectual property rights vs. Expediency:** The proposal to use a rival company's patented compounds raises issues of intellectual property theft and unfair competition.
 - This presents a **dilemma between respecting legal and ethical boundaries** in research and achieving faster results.

3. What course of action should Dr. Sharma take in this scenario?

- **Refuse Unethical Shortcuts:** Dr. Sharma should firmly reject any proposals to **manipulate data, selectively report results, or bypass informed consent procedures**.
 - These actions are fundamentally unethical and could harm patients.
- **Explore Ethical Ways to Expedite the Process:** Collaborate with regulatory bodies to establish an **accelerated review process for urgent treatments**, without compromising on safety standards.
 - **Increase resources allocated to the project**, such as hiring more researchers or expanding lab capacity.
 - Implement **parallel processing of different research phases** where possible and safe to do so.
- **Prioritize Transparency:** Commit to **full disclosure of all trial results**, both positive and negative. This maintains scientific integrity and public trust.
- **Leverage Technology:** Recommend implementing advanced AI and data analytics tools to optimize research and clinical trials.
 - These technologies can **automate data collection, enhance predictive modeling, and identify trends**, ultimately accelerating the research process.
 - By utilizing machine learning algorithms, the team can efficiently analyze vast datasets, ensuring timely insights while maintaining rigorous quality standards.
- **Respect Intellectual Property Rights:** Abandon any plans to use patented compounds from rival companies without permission.

- Instead, explore legal collaboration or **licensing agreements if those compounds are crucial.**
- **Communicate clearly with stakeholders:** Explain to company leadership the ethical issues at stake and the potential long-term consequences of taking shortcuts.
 - Emphasize that maintaining integrity **is crucial for the company's reputation and long-term success.**
- **Whistleblowing:** If pressures from the company become unbearable, Dr. Sharma should consider whistleblower protections to safeguard against potential retaliation.
 - Seeking advice from external ethics committees or legal counsel can provide valuable guidance and support.
 - This step ensures that **ethical standards are upheld and allows Dr. Sharma to report any unethical practices** or safety concerns without compromising their career or integrity.
- **Focus on Patient Safety and Consent:** Ensure all trial participants are **fully informed and have given proper consent.** Implement robust safety monitoring protocols.

Conclusion:

By following the above approach, Dr. Sharma can **balance the urgent need for a treatment with ethical considerations, scientific integrity, and long-term thinking.** This course of action aims to expedite the research process ethically, without compromising on patient safety or scientific standards. It will **not just affect this single case but could set a precedent for how her team and company handle future ethical issues.** This approach also protects Dr. Sharma's professional integrity, the company's reputation, and ultimately **serves the public interest by ensuring the development of a safe and effective treatment.**

PDF Reference URL: <https://www.drishtiias.com/mains-practice-question/question-8497/pnt>

